Published in Br J Ophthalmol on August 01, 2004
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology (2014) 0.99
Value based medicine. Br J Ophthalmol (2004) 0.90
[Value-based medicine in ophthalmology]. Ophthalmologe (2006) 0.85
The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration. Trans Am Ophthalmol Soc (2007) 0.83
Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2013) 0.78
Utility values in Japanese patients with exudative age-related macular degeneration. Jpn J Ophthalmol (2011) 0.77
Dynamics of retinal function after multiple photodynamic therapies in age-related macular degeneration: a report of cases. Doc Ophthalmol (2006) 0.77
Early health economic evaluation of the future potential of next generation artificial vision systems for treating blindness in Germany. Health Econ Rev (2014) 0.77
The quality of pharmacoeconomic evaluations of age-related macular degeneration therapeutics: a systematic review and quantitative appraisal of the evidence. Br J Ophthalmol (2010) 0.75
[Photodynamic therapy of AMD for the first (better sight) and the second (worse sight) eyes]. Ophthalmologe (2007) 0.75
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol (2001) 21.37
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ (1992) 10.40
Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology (1995) 4.28
Age-related macular degeneration. Surv Ophthalmol (1988) 4.18
How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol (2003) 3.07
The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology (2001) 3.04
Utility values and age-related macular degeneration. Arch Ophthalmol (2000) 2.48
Physiological factors associated with falls in an elderly population. J Am Geriatr Soc (1991) 2.37
"Smoking is a major cause of blindness". Med J Aust (1999) 2.27
Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol (1994) 2.16
Health care economic analyses and value-based medicine. Surv Ophthalmol (2003) 1.83
Visual risk factors for hip fracture in older people. J Am Geriatr Soc (2003) 1.80
Utility values associated with blindness in an adult population. Br J Ophthalmol (2001) 1.79
Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci (2004) 1.73
Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol (2002) 1.71
Impact of visual impairment on use of community support services by elderly persons: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci (1999) 1.70
Visual impairment, age-related cataract, and mortality. Arch Ophthalmol (2001) 1.55
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Arch Ophthalmol (2002) 1.53
Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess (2003) 1.46
Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. Clin Experiment Ophthalmol (2000) 1.45
The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch Ophthalmol (1995) 1.35
Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol (2002) 1.31
Visual impairment and nursing home placement in older Australians: the Blue Mountains Eye Study. Ophthalmic Epidemiol (2003) 1.21
Vision and low self-rated health: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci (2000) 1.16
Direct costs of blindness in Australia. Clin Experiment Ophthalmol (2000) 1.14
Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol (2004) 1.08
The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc (2001) 1.06
Utilities associated with diabetic retinopathy: results from a Canadian sample. Br J Ophthalmol (2003) 1.04
Federal budgetary costs of blindness. Milbank Q (1992) 1.04
Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. Biol Rev Camb Philos Soc (1966) 17.89
Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell (1987) 14.62
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet (2007) 6.82
Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med (1997) 6.09
Functions of the exosome in rRNA, snoRNA and snRNA synthesis. EMBO J (1999) 5.68
Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology (1996) 5.36
Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology (2001) 5.06
The yeast exosome and human PM-Scl are related complexes of 3' --> 5' exonucleases. Genes Dev (1999) 4.95
Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest (1997) 4.31
Acid-base titration across the membrane system of rat-liver mitochondria. Catalysis by uncouplers. Biochem J (1967) 4.24
Proton-coupled beta-galactoside translocation in non-metabolizing Escherichia coli. J Bioenerg (1972) 4.24
Estimation of membrane potential and pH difference across the cristae membrane of rat liver mitochondria. Eur J Biochem (1969) 3.97
Translocations through natural membranes. Adv Enzymol Relat Areas Mol Biol (1967) 3.77
Vectorial chemistry and the molecular mechanics of chemiosmotic coupling: power transmission by proticity. Biochem Soc Trans (1976) 3.58
Cooperative hernia study. Pain in the postrepair patient. Ann Surg (1996) 3.57
Performance and conservation of osmotic work by proton-coupled solute porter systems. J Bioenerg (1973) 3.41
Possible molecular mechanisms of the protonmotive function of cytochrome systems. J Theor Biol (1976) 3.41
Keilin's respiratory chain concept and its chemiosmotic consequences. Science (1979) 3.23
Translocation of some anions cations and acids in rat liver mitochondria. Eur J Biochem (1969) 3.13
The POP1 gene encodes a protein component common to the RNase MRP and RNase P ribonucleoproteins. Genes Dev (1994) 3.12
Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry (2001) 3.07
Chemiosmotic coupling in energy transduction: a logical development of biochemical knowledge. J Bioenerg (1972) 3.02
Proton-translocation phosphorylation in mitochondria, chloroplasts and bacteria: natural fuel cells and solar cells. Fed Proc (1967) 2.96
Prospective study of the impact of fear of falling on activities of daily living, SF-36 scores, and nursing home admission. J Gerontol A Biol Sci Med Sci (2000) 2.89
Proton/sodium ion antiport in Escherichia coli. Biochem J (1974) 2.89
Prevalence and causes of amblyopia in an adult population. Ophthalmology (1998) 2.84
Smoking and age-related macular degeneration: a review of association. Eye (Lond) (2005) 2.77
The polarity of proton translocation in some photosynthetic microorganisms. Eur J Biochem (1969) 2.74
Home visits by an occupational therapist for assessment and modification of environmental hazards: a randomized trial of falls prevention. J Am Geriatr Soc (1999) 2.74
Stoicheiometry of lactose-H+ symport across the plasma membrane of Escherichia coli. Biochem J (1973) 2.57
Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc (1998) 2.51
Degradation of ribosomal RNA precursors by the exosome. Nucleic Acids Res (2000) 2.47
Acid-base titration across the plasma membrane of Micrococcus denitrificans: factors affecting the effective proton conductance and the respiratory rate. J Bioenerg (1970) 2.45
Effect of primary-care spirometry on the diagnosis and management of COPD. Eur Respir J (2006) 2.34
The protonmotive Q cycle: a general formulation. FEBS Lett (1975) 2.32
Refractive errors in an older population: the Blue Mountains Eye Study. Ophthalmology (1999) 2.29
"Smoking is a major cause of blindness". Med J Aust (1999) 2.27
The Ninth Sir Hans Krebs Lecture. Compartmentation and communication in living systems. Ligand conduction: a general catalytic principle in chemical, osmotic and chemiosmotic reaction systems. Eur J Biochem (1979) 2.25
Optimal dietary approaches for prevention of type 2 diabetes: a life-course perspective. Diabetologia (2010) 2.23
Hip protectors improve falls self-efficacy. Age Ageing (2000) 2.22
Stoichiometry of proton translocation through the respiratory chain and adenosine triphosphatase systems of rat liver mitochondria. Nature (1965) 2.19
Respiration-driven proton translocation in Micrococcus denitrificans. J Bioenerg (1971) 2.17
Outdoor activity and myopia in Singapore teenage children. Br J Ophthalmol (2009) 2.13
Protonmotive redox mechanism of the cytochrome b-c1 complex in the respiratory chain: protonmotive ubiquinone cycle. FEBS Lett (1975) 2.07
Knowledge and beliefs about common eye diseases. Aust N Z J Ophthalmol (1997) 2.06
Medications and cataract. The Blue Mountains Eye Study. Ophthalmology (1998) 2.05
The management of oesophageal carcinoma: radiotherapy or surgery? Cost considerations. Eur J Cancer Clin Oncol (1989) 2.00
Validation of self-reported hearing loss. The Blue Mountains Hearing Study. Int J Epidemiol (2001) 2.00
Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol (2008) 1.98
British Medical Association enters GM-crop affray. Lancet (1999) 1.94
Vision screening for frail older people: a randomised trial. Br J Ophthalmol (2008) 1.93
Clustering of modified nucleotides at the functional center of bacterial ribosomal RNA. FASEB J (1993) 1.93
Risk factors for age-related maculopathy: the Visual Impairment Project. Arch Ophthalmol (2001) 1.88
Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care (2001) 1.84
Retinopathy in older persons without diabetes and its relationship to hypertension. Arch Ophthalmol (1998) 1.84
Transcriptional activation by Myc is under negative control by the transcription factor AP-2. EMBO J (1995) 1.82
Retinopathy predicts coronary heart disease mortality. Heart (2008) 1.80
The development of performance and cost indicators for preschool immunisation. Arch Dis Child (1986) 1.77
Increasing response rates in telephone surveys: a randomized trial. J Public Health Med (1995) 1.70
Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol (1998) 1.70
Impact of visual impairment on use of community support services by elderly persons: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci (1999) 1.70
Propofol and ECT. Br J Psychiatry (1992) 1.68
Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry (1995) 1.67
Smoking and age-related maculopathy. The Blue Mountains Eye Study. Arch Ophthalmol (1996) 1.67
Vectorial chemiosmotic processes. Annu Rev Biochem (1977) 1.66
Incidence of nursing home placement in a defined community. Med J Aust (2001) 1.65
The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology (2000) 1.64
The nature of bipolar depression: implications for the definition of melancholia. J Affect Disord (2000) 1.64
Effects of cataract type and location on visual function: the Blue Mountains Eye Study. Eye (Lond) (2004) 1.62
Self-reported dark red bleeding as a marker comparable with occult blood testing in screening for large bowel neoplasms. Br J Surg (1983) 1.59
Covered expandable tracheal stents in the management of benign tracheal granulation tissue formation. Ann Thorac Surg (2000) 1.59
Proton translocation coupled to ATP hydrolysis in rat liver mitochondria. Eur J Biochem (1968) 1.57
Visual impairment, age-related cataract, and mortality. Arch Ophthalmol (2001) 1.55
Prevalence of pterygium and pinguecula: the Blue Mountains Eye Study. Aust N Z J Ophthalmol (1998) 1.53
Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother (2001) 1.52
Renal impairment and anaemia in a population-based study of older people. Intern Med J (2004) 1.51
Cystadenomas of the liver: a spectrum of disease. Can J Surg (2001) 1.51
The role of smart cards in France. Health Data Manag (1998) 1.49
Retinal microvascular changes and subsequent vascular events after ischemic stroke. Neurology (2011) 1.49
Synthesis of adenosine triphosphate by a protonmotive force in rat liver mitochondria. Nature (1966) 1.48
Spinocerebellar ataxia type 2: clinical features of a pedigree displaying prominent frontal-executive dysfunction. Arch Neurol (1999) 1.48
Chemiosmotic hypothesis of oxidative phosphorylation. Nature (1967) 1.47
Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. Clin Experiment Ophthalmol (2000) 1.45
Does intra-arterial thrombolysis have a role as first-line intervention in acute ischaemic stroke? Intern Med J (2011) 1.43
Study of cardiac rhythm in healthy newborn infants. Br Heart J (1980) 1.43
Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ (2004) 1.42
Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. Mol Imaging Biol (2009) 1.42
Consequences of amblyopia on education, occupation, and long term vision loss. Br J Ophthalmol (2004) 1.42
The proton-translocating ATPase of Escherichia coli. FEBS Lett (1974) 1.41
Posttransplant cataract: lessons from kidney-pancreas transplantation. Transplantation (2000) 1.41
Decompressive craniectomy in traumatic brain injury: the randomized multicenter RESCUEicp study (www.RESCUEicp.com). Acta Neurochir Suppl (2006) 1.41
Crash and boom: the rise and fall of biotechnology. Lancet (1997) 1.40
Monoamine oxidase inhibitors (MAOI) or reversible inhibitors of monoamine oxidase (RIMA)/tricyclic antidepressant (TCA) combination therapy. Aust N Z J Psychiatry (1992) 1.40
Struggle worldwide to regain consumers' faith in food. Lancet (1997) 1.40
Neural network subtyping of depression. Aust N Z J Psychiatry (1998) 1.39
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. Int J Clin Pract (2009) 1.39
Counting the costs of mammography screening: first year results from the Sydney study. Med J Aust (1990) 1.39
Methylation sites in Escherichia coli ribosomal RNA: localization and identification of four new sites of methylation in 23S rRNA. Biochemistry (1992) 1.39
Refractive associations with cataract: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci (1999) 1.38
Depression sub-typing: unitary, binary or arbitrary? Aust N Z J Psychiatry (1991) 1.38